“Concurrent EGFR and KRAS mutations in non-small cell lung cancer: Challenging the paradigm of linear targeted therapy”, J Curr Biomed Rep, vol. 6, no. 2, pp. 45–46, Jun. 2025, doi: 10.61882/jcbior.6.2.299.